<b>Optimal Aminoglycoside Therapy Following the Sepsis: How Much Is Too Much?</b>

AuthorLaleh Mahmoudien
AuthorRamin Niknamen
AuthorSarah Mousavien
AuthorArezoo Ahmadien
AuthorHooshyar Honarmanden
AuthorShadi Ziaieen
AuthorMojtaba Mojtahedzadehen
Issued Date2013-04-30en
AbstractSevere sepsis and septic shock are major problems as the result of high rates morbidity and mortality in intensive care units (ICUs). In the presence of septic shock, each hour of delay in the administration of effective antibiotics is associated with a measurable increase in mortality. Aminoglycosides are effective broad-spectrum antibiotics that are commonly used in ICUs for the treatment of life-threatening Gram-negative infections and as a part of empiric therapy for severe sepsis and septic shock. Knowledge of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the antibiotics used for the management of critically ill patients is essential for selecting the antibiotic dosing regimens and improving patient outcome.en
DOIhttps://doi.org/10.22037/ijpr.2013.1298en
KeywordSepsisen
KeywordSeptic shocken
KeywordAminoglycosidesen
KeywordPharmacokineticen
KeywordCritically illen
PublisherBrieflandsen
Title<b>Optimal Aminoglycoside Therapy Following the Sepsis: How Much Is Too Much?</b>en
TypeOriginal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ijpr-12-261.pdf
Size:
539.45 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF